{"result": "I'll help you identify the entities and relationships in the given text.\n\nEntity_types: organization, person, geo, event\n\nText: Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clin Breast Cancer 2018;18(4):328\u201335.\n[81] Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol 2017;28(1):103\u20139.\n[82] Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clini Oncol Off J Am Soc Clin Oncol 2013;31(14):1719\u201325.\n[83] Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial. J Clin Oncol 2013;31(15):1726\u201333.\n\nOutput:\n\n(\"entity\"<|>\"Pierga JY\"<|>\"person\"<|>\"Pierga JY is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Bidard FC\"<|>\"person\"<|>\"Bidard FC is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Autret A\"<|>\"person\"<|>\"Autret A is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Petit T\"<|>\"person\"<|>\"Petit T is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Andre F\"<|>\"person\"<|>\"Andre F is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Dalenc F\"<|>\"person\"<|>\"Dalenc F is an author of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\")##\n(\"entity\"<|>\"Gianni L\"<|>\"person\"<|>\"Gianni L is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Romieu GH\"<|>\"person\"<|>\"Romieu GH is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Lichinitser M\"<|>\"person\"<|>\"Lichinitser M is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Serrano SV\"<|>\"person\"<|>\"Serrano SV is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Mansutti M\"<|>\"person\"<|>\"Mansutti M is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Pivot X\"<|>\"person\"<|>\"Pivot X is an author of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\")##\n(\"entity\"<|>\"Cameron D\"<|>\"person\"<|>\"Cameron D is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"entity\"<|>\"Brown J\"<|>\"person\"<|>\"Brown J is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"entity\"<|>\"Dent R\"<|>\"person\"<|>\"Dent R is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"entity\"<|>\"Jackisch C\"<|>\"person\"<|>\"Jackisch C is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"entity\"<|>\"Mackey J\"<|>\"person\"<|>\"Mackey J is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"entity\"<|>\"Pivot X\"<|>\"person\"<|>\"Pivot X is an author of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\")##\n(\"relationship\"<|>\"Pierga JY\"<|>\"Bidard FC\"<|>\"Pierga JY and Bidard FC are co-authors of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Pierga JY\"<|>\"Autret A\"<|>\"Pierga JY and Autret A are co-authors of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Pierga JY\"<|>\"Petit T\"<|>\"Pierga JY and Petit T are co-authors of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Pierga JY\"<|>\"Andre F\"<|>\"Pierga JY and Andre F are co-authors of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Pierga JY\"<|>\"Dalenc F\"<|>\"Pierga JY and Dalenc F are co-authors of a study on circulating tumour cells and pathological complete response in inflammatory breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Gianni L\"<|>\"Romieu GH\"<|>\"Gianni L and Romieu GH are co-authors of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Gianni L\"<|>\"Lichinitser M\"<|>\"Gianni L and Lichinitser M are co-authors of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Gianni L\"<|>\"Serrano SV\"<|>\"Gianni L and Serrano SV are co-authors of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Gianni L\"<|>\"Mansutti M\"<|>\"Gianni L and Mansutti M are co-authors of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Gianni L\"<|>\"Pivot X\"<|>\"Gianni L and Pivot X are co-authors of a study on AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.\"<|>8)##\n(\"relationship\"<|>\"Cameron D\"<|>\"Brown J\"<|>\"Cameron D and Brown J are co-authors of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\"<|>8)##\n(\"relationship\"<|>\"Cameron D\"<|>\"Dent R\"<|>\"Cameron D and Dent R are co-authors of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\"<|>8)##\n(\"relationship\"<|>\"Cameron D\"<|>\"Jackisch C\"<|>\"Cameron D and Jackisch C are co-authors of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\"<|>8)##\n(\"relationship\"<|>\"Cameron D\"<|>\"Mackey J\"<|>\"Cameron D and Mackey J are co-authors of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\"<|>8)##\n(\"relationship\"<|>\"Cameron D\"<|>\"Pivot X\"<|>\"Cameron D and Pivot X are co-authors of a study on Adjuvant bevacizumab-containing therapy in triple-negative breast cancer: a randomized phase III trial.\"<|>8)<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n\n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>\n\n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n\n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n\n4. When finished, output <|COMPLETE|>\n\n######################\n-Examples-\n######################\nExample 1:\n\nEntity_types: [person, technology, mission, organization, location]\nText:\nwhile Alex clenched his jaw, the buzz of frustration dull against the backdrop of Taylor's authoritarian certainty. It was this competitive undercurrent that kept him alert, the sense that his and Jordan's shared commitment to discovery was an unspoken rebellion against Cruz's narrowing vision of control and order.\n\nThen Taylor did something unexpected. They paused beside Jordan and, for a moment, observed the device with something akin to reverence. \u201cIf this tech can be understood...\" Taylor said, their voice quieter, \"It could change the game for us. For all of us.\u201d\n\nThe underlying dismissal earlier seemed to falter, replaced by a glimpse of reluctant respect for the gravity of what lay in their hands. Jordan looked up, and for a fleeting heartbeat, their eyes locked with Taylor's, a wordless clash of wills softening into an uneasy truce.\n\nIt was a small transformation, barely perceptible, but one that Alex noted with an inward nod. They had all been brought here by different paths\n################\nOutput:\n(\"entity\"<|>\"Alex\"<|>\"person\"<|>\"Alex is a character who experiences frustration and is observant of the dynamics among other characters.\")##\n(\"entity\"<|>\"Taylor\"<|>\"person\"<|>\"Taylor is portrayed with authoritarian certainty and shows a moment of reverence towards a device, indicating a change in perspective.\")##\n(\"entity\"<|>\"Jordan\"<|>\"person\"<|>\"Jordan shares a commitment to discovery and has a significant interaction with Taylor regarding a device.\")##\n(\"entity\"<|>\"Cruz\"<|>\"person\"<|>\"Cruz is associated with a vision of control and order, influencing the dynamics among other characters.\")##\n(\"entity\"<|>\"The Device\"<|>\"technology\"<|>\"The Device is central to the story, with potential game-changing implications, and is revered by Taylor.\")##\n(\"relationship\"<|>\"Alex\"<|>\"Taylor\"<|>\"Alex is affected by Taylor's authoritarian certainty and observes changes in Taylor's attitude towards the device.\"<|>7)##\n(\"relationship\"<|>\"Alex\"<|>\"Jordan\"<|>\"Alex and Jordan share a commitment to discovery, which contrasts with Cruz's vision.\"<|>6)##\n(\"relationship\"<|>\"Taylor\"<|>\"Jordan\"<|>\"Taylor and Jordan interact directly regarding the device, leading to a moment of mutual respect and an uneasy truce.\"<|>8)##\n(\"relationship\"<|>\"Jordan\"<|>\"Cruz\"<|>\"Jordan's commitment to discovery is in rebellion against Cruz's vision of control and order.\"<|>5)##\n(\"relationship\"<|>\"Taylor\"<|>\"The Device\"<|>\"Taylor shows reverence towards the device, indicating its importance and potential impact.\"<|>9)<|COMPLETE|>\n#############################\nExample 2:\n\nEntity_types: [person, technology, mission, organization, location]\nText:\nThey were no longer mere operatives; they had become guardians of a threshold, keepers of a message from a realm beyond stars and stripes. This elevation in their mission could not be shackled by regulations and established protocols\u2014it demanded a new perspective, a new resolve.\n\nTension threaded through the dialogue of beeps and static as communications with Washington buzzed in the background. The team stood, a portentous air enveloping them. It was clear that the decisions they made in the ensuing hours could redefine humanity's place in the cosmos or condemn them to ignorance and potential peril.\n\nTheir connection to the stars solidified, the group moved to address the crystallizing warning, shifting from passive recipients to active participants. Mercer's latter instincts gained precedence\u2014 the team's mandate had evolved, no longer solely to observe and report but to interact and prepare. A metamorphosis had begun, and Operation: Dulce hummed with the newfound frequency of their daring, a tone set not by the earthly\n#############\nOutput:\n(\"entity\"<|>\"Washington\"<|>\"location\"<|>\"Washington is a location where communications are being received, indicating its importance in the decision-making process.\")##\n(\"entity\"<|>\"Operation: Dulce\"<|>\"mission\"<|>\"Operation: Dulce is described as a mission that has evolved to interact and prepare, indicating a significant shift in objectives and activities.\")##\n(\"entity\"<|>\"The team\"<|>\"organization\"<|>\"The team is portrayed as a group of individuals who have transitioned from passive observers to active participants in a mission, showing a dynamic change in their role.\")##\n(\"relationship\"<|>\"The team\"<|>\"Washington\"<|>\"The team receives communications from Washington, which influences their decision-making process.\"<|>7)##\n(\"relationship\"<|>\"The team\"<|>\"Operation: Dulce\"<|>\"The team is directly involved in Operation: Dulce, executing its evolved objectives and activities.\"<|>9)<|COMPLETE|>\n#############################\nExample 3:\n\nEntity_types: [person, role, technology, organization, event, location, concept]\nText:\ntheir voice slicing through the buzz of activity. \"Control may be an illusion when facing an intelligence that literally writes its own rules,\" they stated stoically, casting a watchful eye over the flurry of data.\n\n\"It's like it's learning to communicate,\" offered Sam Rivera from a nearby interface, their youthful energy boding a mix of awe and anxiety. \"This gives talking to strangers' a whole new meaning.\"\n\nAlex surveyed his team\u2014each face a study in concentration, determination, and not a small measure of trepidation. \"This might well be our first contact,\" he acknowledged, \"And we need to be ready for whatever answers back.\"\n\nTogether, they stood on the edge of the unknown, forging humanity's response to a message from the heavens. The ensuing silence was palpable\u2014a collective introspection about their role in this grand cosmic play, one that could rewrite human history.\n\nThe encrypted dialogue continued to unfold, its intricate patterns showing an almost uncanny anticipation\n#############\nOutput:\n(\"entity\"<|>\"Sam Rivera\"<|>\"person\"<|>\"Sam Rivera is a member of a team working on communicating with an unknown intelligence, showing a mix of awe and anxiety.\")##\n(\"entity\"<|>\"Alex\"<|>\"person\"<|>\"Alex is the leader of a team attempting first contact with an unknown intelligence, acknowledging the significance of their task.\")##\n(\"entity\"<|>\"Control\"<|>\"concept\"<|>\"Control refers to the ability to manage or govern, which is challenged by an intelligence that writes its own rules.\")##\n(\"entity\"<|>\"Intelligence\"<|>\"concept\"<|>\"Intelligence here refers to an unknown entity capable of writing its own rules and learning to communicate.\")##\n(\"entity\"<|>\"First Contact\"<|>\"event\"<|>\"First Contact is the potential initial communication between humanity and an unknown intelligence.\")##\n(\"entity\"<|>\"Humanity's Response\"<|>\"event\"<|>\"Humanity's Response is the collective action taken by Alex's team in response to a message from an unknown intelligence.\")##\n(\"relationship\"<|>\"Sam Rivera\"<|>\"Intelligence\"<|>\"Sam Rivera is directly involved in the process of learning to communicate with the unknown intelligence.\"<|>9)##\n(\"relationship\"<|>\"Alex\"<|>\"First Contact\"<|>\"Alex leads the team that might be making the First Contact with the unknown intelligence.\"<|>10)##\n(\"relationship\"<|>\"Alex\"<|>\"Humanity's Response\"<|>\"Alex and his team are the key figures in Humanity's Response to the unknown intelligence.\"<|>8)##\n(\"relationship\"<|>\"Control\"<|>\"Intelligence\"<|>\"The concept of Control is challenged by the Intelligence that writes its own rules.\"<|>7)<|COMPLETE|>\n#############################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Endocrine Therapy as Preoperative Treatment of In\ufb02ammatory Breast\nCancer. Clin Breast Cancer 2018;18(4):328\u201335.\n[81] Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, et al. Circulating\ntumour cells and pathological complete response: independent prognostic\nfactors in in\ufb02ammatory breast cancer in a pooled analysis of two multicentre\nphase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined\nwith bevacizumab. Ann Oncol 2017;28(1):103\u20139.\n[82] Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al.\nAVEREL: a randomized phase III Trial evaluating bevacizumab in combination\nwith docetaxel and trastuzumab as \ufb01rst-line therapy for HER2-positive\nlocally recurrent/metastatic breast cancer. J Clini Oncol Off J Am Soc Clin\nOncol 2013;31(14):1719\u201325.\n[83] Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant\nbevacizumab-containing\ntherapy\nin\ntriple-negative\nbreast\n######################\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 3000, "n": null}}